How much revenue does Kaleido Biosciences make?

Kaleido Biosciences reported $1.10 million in revenue for fiscal year 2021, up 13.2% from $975,000 in fiscal year 2020.

What companies are similar to Kaleido Biosciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Radiko Holdings Corp. (GEATF), Baudax Bio, Inc. (BXRXQ), THE Flowr Corporation (FLWPF), ONE Bio Corp. (ONBI).

Kaleido Biosciences, Inc. (KLDO) Stock

About Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immu...

At a glance

Kaleido Biosciences reported revenue of $1.10 million for fiscal year 2021, up 13.2% from fiscal year 2020, and net income of -$90.29 million.

Figures from company filings; latest fiscal year ended December 31, 2021.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.